Adarx names Shawver chair
Plus: Formation bolsters team and updates from Spyglass, Generate, Achieve, Sangamo, X4, Neumirna, Worldwide Clinical Trials, Mink
San Diego-based RNA therapeutics company Adarx Pharmaceuticals Inc. appointed Laura Shawver as chair. Shawver was CEO of Capstan Therapeutics Inc., which AbbVie Inc. (NYSE:ABBV) acquired in June for up to $2.1 billion. That was the second 10-figure buyout for Shawver; she was also president and CEO of Synthorx Inc. through its $2.5 billion acquisition by Sanofi (Euronext:SAN; NASDAQ:SNY), announced in 2019. Shawver chairs Danish antibody-drug conjugate company Adcendo ApS.
Formation Bio Inc. hired Louis Brenner as CMO and Daniel Neil as CTO, and added a pair of new senior advisers. Brenner was president and CEO of Hopewell Therapeutics Inc., while Neil was chief data officer at Tessera Therapeutics Inc. Frank D’Amelio and Dashyant Dhanak joined as strategic advisers and members of the company’s Investment Advisory Committee, with D’Amelio being named co-chair. Formation acquires clinical candidates that it develops in-house using an AI process with a goal of faster and more efficient drug development...